CureVac (CVAC) Stock Price

The business model of CureVac NV focuses on the development of transformative messenger RNA (mRNA) therapeutics and vaccines. By leveraging its proprietary mRNA platform, CureVac aims to address various diseases and medical conditions across multiple therapeutic areas, including infectious diseases, oncology, and rare diseases. Their mRNA technology allows for the production of vaccine candidates and therapeutic proteins, which can be customized to target specific diseases. This innovative approach offers potential advantages such as rapid development, scalability, and adaptability. As a leading biopharmaceutical company, CureVac NV seeks to revolutionize the field of medicine through the use of mRNA to provide innovative treatment options for patients worldwide.

CureVac NV is primarily active in the biotechnology industry.

CureVac NV is a biopharmaceutical company specializing in developing messenger RNA (mRNA) therapeutics and vaccines. Founded in 2000, CureVac has a rich history of groundbreaking mRNA research. The company is headquartered in Tübingen, Germany, and has expanded its presence globally, including the establishment of CureVac Inc. in the United States. CureVac has pioneered the use of mRNA as a platform for various therapeutic applications, including cancer treatments, infectious diseases, and rare diseases. As a leading player in the field, CureVac has collaborated with numerous strategic partners and received significant funding for its innovative mRNA technology, demonstrating its promising potential in revolutionizing the medical industry.

CureVac NV, a renowned biopharmaceutical company, has attained several significant milestones in its journey. Notably, CureVac NV successfully completed its initial public offering (IPO) in August 2020, raising substantial capital for its research and development activities. Moreover, the company has made noteworthy advancements in the development of mRNA-based vaccines and therapeutics, showcasing promising results in preclinical and clinical trials. CureVac NV has also established strategic partnerships with various leading pharmaceutical companies, such as Bayer, GSK, and the Bill & Melinda Gates Foundation, further strengthening its research and commercialization capabilities. With its pioneering approach and collaborative efforts, CureVac NV continues to revolutionize the field of mRNA-based healthcare solutions.

CureVac NV is primarily present in various countries and regions. The company's presence spans across Europe, including Germany, Switzerland, and Austria, where its headquarters and research facilities are located. CureVac NV also has a strong presence in the United States, with operations in Cambridge, Massachusetts. The company's global expansion efforts have led to its presence in other regions, such as Latin America, Africa, and Asia, as it collaborates with partners and conducts clinical trials worldwide. With its widespread presence and international collaborations, CureVac NV is dedicated to advancing mRNA-based technologies and developing innovative solutions on a global scale.

CureVac NV represents a commitment to transforming the lives of patients through groundbreaking mRNA technology. With a strong corporate philosophy centered on innovation, quality, and collaboration, the company strives to develop and deliver mRNA-based therapeutics and vaccines to address a wide range of diseases, including cancer and infectious diseases. CureVac NV's values are built upon scientific excellence, patient-centricity, and sustainability. By harnessing the power of mRNA, the company aims to revolutionize healthcare and improve global health outcomes. Through continuous research and strategic partnerships, CureVac NV demonstrates its dedication to advancing the field of mRNA-based medicine and making a positive impact on society.

Analysts currently set an average price target of 5.00 EUR for the CureVac stock (median: 5.00 EUR), implying +22.6 % versus the latest price. The consensus is based on 11 analyst ratings.

CureVac Analyst Price Targets 2026

11 analysts currently rate the CureVac stock: 6 recommend buying, 5 holding and 0 selling. For 2026, analysts expect CureVac to generate revenue of 88.19 M EUR and earnings per share of -0.50 EUR.

CureVac Analyst Price Targets 2026

The CureVac share (CVAC) is listed on 10 stock exchanges, including: NASDAQ (CVAC), London (0A9E.L), SIX (Zürich) (5CV.SW), XETRA (5CV.DE), Frankfurt (5CV.F), München (5CV.MU), Düsseldorf (5CV.DU), Hamburg (5CV.HM).

CureVac NV is a biotechnology company based in Tübingen, specializing in the development of mRNA-based therapies and vaccines. The company's business model is based on basic research and the development of innovative technologies for the production of mRNA-based products. One of CureVac's key areas is the development of mRNA vaccines. The company uses its platform technology to produce mRNA molecules that stimulate the body's immune system and induce a protective immune response. CureVac has already developed several vaccine candidates for diseases such as COVID-19 and cancer, which are currently in clinical development. Another focus of the company is the development of mRNA therapies. This involves using mRNA technology to produce therapeutic proteins or antibodies in the body to treat diseases. CureVac's therapy areas include cancer, rare diseases, and infectious diseases. To develop and manufacture these technologies, CureVac has its own research and development as well as production facilities. The company utilizes mRNA technology to produce clinical and commercial quantities of mRNA products. CureVac follows a highly automated and standardized production process to ensure high quality and large quantities of products. Collaboration with industry and scientific partners is also an important part of CureVac's business model. The company has formed partnerships with various pharmaceutical companies to jointly work on the development of mRNA-based therapies and vaccines. Additionally, CureVac works closely with universities and research institutions to advance basic research on mRNA technology. To expand the applications of its technology, CureVac continuously invests in researching new mRNA platforms and developing new technologies to improve the delivery of mRNA products in the body. This will allow for effective treatment of a wider range of diseases. In summary, CureVac's business model is based on the development and application of mRNA technology for the production of therapeutic proteins, antibodies, and vaccines. The company engages in both research and development activities and operates its own production facility, while collaborating with industry and scientific partners. With the use of its platform technology and continuous innovation, CureVac aims to effectively treat a wider range of diseases.

The expected revenue of CureVac is 88.19 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CureVac is -111.86 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CureVac is currently -8.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CureVac stock.

The price-to-sales ratio (P/S) of CureVac is currently 10.37. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CureVac stock.

The Eulerpool Quality Score for CureVac is 7/10.

The ISIN of CureVac is NL0015436031. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of CureVac is A2P71U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of CureVac is CVAC. The ticker symbol is used to trade CureVac shares on the stock exchange.